Arterial attenuation in individualized computed tomography pulmonary angiography injection protocol adjusted based on the patient’s body mass index

Leila Jamali1, Babak Alikhani2, Tobias Getzin1, Kristina Imeen Ringe1, Frank K. Wacker1, Hans-Jürgen Raatschen1

1Department of Diagnostic and Interventional Radiology, Hannover Medical School, Hannover, Germany, 2Center for Radiology and Nuclear Medicine, Diakovere gGmbH, Hannover, Germany

Background: The aim of this study was to optimize computed tomography pulmonary angiography (CTPA) protocols with regard to improve vascular attenuation without increasing contrast media (CM) volumes. Therefore, we compared the standard CTPA protocol to an individualized contrast media injection protocols adjusted for the patient’s body mass index (BMI). Materials and Methods: Two groups of 295 patients with suspected pulmonary embolism (PE) have been receiving CTPA. Group 1 received a standard protocol without taking patient’s BMI into account. Group 2 received a CTPA scan, where dose and flow rate of CM injections were adjusted for the patient’s BMI. Images were retrospectively analyzed by drawing regions of interests in defined positions in the superior vena cava, descending aorta, the pulmonary main trunk as well as the left and right lower lobe arteries. Intravascular attenuation, contrast volumes, and flow rates were compared using unpaired t-tests. Furthermore, a qualitative image analysis was performed by two experienced readers blinded for the protocol used for image acquisition to evaluate the image quality and arterial attenuation. Results: Patient’s BMI was similar in both the groups (27.5 ± 1.5 kg/m² vs. 28.4 ± 2.1 kg/m²; P = 0.67). Contrast volumes were lower (54.2 ± 4.8 ml vs. 55 ml; P < 0.05), and flow rates (4.1 ± 0.3 ml/s vs. 3.5 ml/s; P < 0.05) were significantly higher in the individualized protocol. The qualitative image analysis yielded an agreement on diagnostic interpretability in the individualized and standard group of 49% and 51% (95% Wilson confidence interval for mean), respectively. Conclusion: An individualized CTPA protocol based on the patient’s BMI reduced the contrast media volume and led to an increased pulmonary artery enhancement improving image quality, particularly in the evaluation of the peripheral pulmonary arteries. Thus, contrast media volumes in CTPA should be adjusted for the patient’s BMI.

Key words: Body mass index, computed tomography pulmonary angiography, contrast media, pulmonary embolism

INTRODUCTION

Pulmonary embolism (PE) is still one of the most common causes of early mortality in acute cardiovascular disease in patients with long hospitalization despite developments in diagnosis and treatment.[1] PE is a complication of underlying venous thrombosis.[2] Epidemiological data indicate that of the more than 1.1 million cases of venous thromboembolism that occur in the European Union each year, approximately one-third are PE cases.[3] With the improved and increased accuracy of diagnosing PE, 25% of those who currently die from PE could be saved.[4] However, the diagnosis of PE may be missed because of its nonspecific clinical symptoms,[5] including chest pain, dyspnea, and syncope. Clinical risk stratification and D-dimer assay can be useful in suspected PE, but D-dimer tests can also be positive in many other conditions that are associated with a procoagulant state.[5] If the clinical
suspicion of PE is high, computed tomography pulmonary angiography (CTPA) is required.\textsuperscript{[7‑10]} CTPA is the method of choice for emboli detection.\textsuperscript{[7‑10]}

To ensure reliable diagnostic accuracy, vascular enhancement in the territory of suspected emboli needs to be optimized with a substantial difference between vascular attenuation and thrombus. However, very strong vascular attenuation can lead to blurring artifacts and result in impaired diagnostic reliability. Thus, optimal bolus geometry and timing considering individual patient parameters and other factors, for example, scan parameters, are necessary to obtain the best results.\textsuperscript{[9‑11]}

Contrast media enhancement in first-pass vascular territories such as pulmonary arteries strongly correlates with the patient’s BMI since large patients have larger blood distribution volumes than small patients which leads to increased contrast dilution. Therefore, patients with high BMI often require higher flow rates and/or increased contrast media volumes.

The purpose of our retrospective study was to analyze vascular attenuation in the pulmonary arteries, superior vena cava, and thoracic aorta, to assess diagnostic reliability, and to compare a standardized injection protocol for CTPA using the same amount of contrast media (CM) and an identical flow rate in each patient with an individualized injection protocol taking into account the individual patient’s body mass index (BMI).

MATERIALS AND METHODS

Study design and participants
Institutional review board approval was waived due to the retrospective approach of the study, and written informed consent including anonymized data use for research was obtained from every patient. The goal of this retrospective study was to evaluate CM attenuation in the pulmonary arteries in patients with suspicion of pulmonary embolism comparing two different approaches in contrast administration. Patients were assigned to the standard protocol (Group 1) or the individualized protocol (Group 2). All patients with known allergic reactions to contrast media as well as patients with known renal failure (eGFR <30 ml/min/1.73 m\textsuperscript{2}), pregnant women, and patients <18 years of age were excluded from the study. In Group 1, one patient had undergone right lobectomy, and in Group 2, one patient had undergone left upper lobe resection and one patient had undergone right pneumonectomy. In an attempt to minimize bias, these patients were excluded from the study.

Before May 2015, all patients were scanned routinely with a standard contrast administration protocol of 55 ml iomeprol 400 (Imeron 400, Bracco Imaging, Konstanz, Germany) at a flow rate of 3.5 ml/s.

From May 2015 to December 2015, a software integrated into the injection pump (Certegra\textsuperscript{®}, Bayer Healthcare, Berlin, Germany) allowing for individualization of CM application was used to optimize vascular attenuation in the territory of interest based on patient weight and height.

A total of 295 patients were included in the study and were divided into two groups including 147 and 148 patients. Group 1 received a standard protocol for CTPA and Group 2 an individualized CM protocol. Height and weight of all patients were recorded at the time of the scan.

Computed tomography pulmonary angiogram protocol
Group 1 consisted of 147 patients routinely scanned with a standard contrast injection protocol of 55 ml iomeprol 400 at a flow rate of 3.5 ml/s without consideration of BMI.

Group 2 consisted of 148 patients scanned with an individualized contrast injection protocol which was made possible by the implementation of a software in the power injector used for contrast media application. To avoid painful injections and to reduce the risk for contrast extravasation, the maximum flow rate was limited to 5.5 ml/s.

Computed tomography imaging protocol
All patients were examined in the supine position. Patients of both the groups underwent computed tomography (CT) examinations with the same imaging protocol (X-ray tube voltage of 100 kVp, dose modulation of X-ray tube current of 30–120 mAs, and noise index of 22) by the use of a clinical 64-slice-CT scanner (GE Lightspeed VCT, GE Healthcare, Waukesha, Wisconsin). The main pulmonary artery was identified and chosen as the level of bolus tracking for the scan. Image acquisition was started when the relative attenuation threshold of 200 HU was exceeded.

Image analysis
Quantitative and qualitative image analysis was performed on high-definition LCD monitors routinely used for reporting CT images (Display: 1.Rx 240, Resolution: 1600 × 1200, Orientation: Landscape). Contrast attenuation was measured on the original 1.2-mm thin transverse images by placing circular regions of interest in the center of the pulmonary trunk, the right and left lower lobe arteries, as well as in the superior vena cava and descending aorta at the level of the main pulmonary trunk.
Qualitative image analysis
Two radiologists with CT experience of more than 10 years blinded for the chosen CTPA protocol independently evaluated CTPA scans in terms of visual qualitative comparisons. For this evaluation, the contrast attenuation was rated on a 2-grade scale (1 diagnosable and 0 not diagnosable) in all segmental arteries.

Statistical analysis
Statistical analysis was performed using Software (IBM SPSS Statistics for Windows, Version 22.0. Armonk, NY: IBM Corp).

The independent sample t-test was used to compare attenuation values between both the protocols and for the comparison of BMI.

Normal distribution was tested using Kolmogorov–Smirnov test. Since the parameters contrast media volume and flow rate did not pass this test, both the groups were analyzed using the nonparametric Mann–Whitney U-test. \( P < 0.05 \) was considered statistically significant.

Subjective image parameters were compared with the Wilson confidence interval for a risk difference between two groups to the confidence level \( 1-\alpha = 95\% \) using GraphPad Prism software (GraphPad 8 Software, Inc, CA, USA). The kappa score for the interreader agreement was used to measure the percentage of agreement.

RESULTS

Patients data
The patients in Group 1 (\( n = 147 \), age 59 ± 17, height 173 ± 10 cm, weight 79 ± 20 kg) consisted of 75 men and 72 women (male-to-female ratio = 1.04). Group 2 (\( n = 148 \), age 62 ± 17, height 170 ± 15 cm, weight 78 ± 21 kg) consisted of 81 men and 68 women (male-to-female ratio = 1.19).

There was no statistically significant difference in the distribution of BMI between the two study groups (Group 1: 28.4 ± 2.1 kg/m\(^2\) [range 17.5–39.8]; Group 2: 27.5 ± 1.5 kg/m\(^2\) [range 18.6–50.0 kg/m\(^2\); \( P = 0.67 \). The demographic characteristics are summarized in Table 1.

Contrast media volumes and enhancement parameters
Significant differences in contrast media volume and administration rate were found between the two groups. While Group 1 had been administered a volume of 55 ml at a constant rate of 3.5 ml/s, the corresponding values in Group 2 were a volume of 54.2 ± 4.8 ml at a flow rate of 4.1 ± 0.3 ml/s, respectively. The results are outlined in Figure 1 and Table 2.

Our results showed that at the same BMI-range, contrast enhancement was slightly higher in all anatomic sites of interest when the individualized injection protocol was used. The obtained results are summarized in Table 3.

Subjective grading of image quality
On the basis of a subjective scoring system, no difference between the two protocols with regard to diagnostic reliability has been observed. The results also indicate, that the differences between both groups evaluated by two readers are not significant.

The kappa score for the interreader agreement was \( \kappa = 0.91 \) for group 1 and \( \kappa = 0.86 \) for group 2. Both the scores indicated “excellent agreement.”

The confidence interval of all segmental arteries that were considered to have sufficient quality for assessment of PE did not significantly differ between Group 1 (mean: 0.49; lower limit: 0.43 and upper limit: 0.55) and Group 2 (mean: 0.51; lower limit: 0.45 and upper limit: 0.57).

Table 1: Demographic characteristics

| Characteristic                  | Group 1 standard protocol | Group 2 individualized protocol | \( P^* \) |
|--------------------------------|---------------------------|--------------------------------|----------|
| Number of patients             | 147                       | 148                            |          |
| Male-to-female ratio           | 1.04                      | 1.19                           |          |
| Age*                          | 59 ± 17                   | 62 ± 17                       | 0.13     |
| BMI (kg/m\(^2\))^\(\pm\) SD\(^\top\)\) | 28.4 ± 2.1 (17.5–39.8)   | 27.5 ± 1.5 (18.6–50.0)         | 0.67     |

*The data are presented as mean±SD. **P values calculated using independentsamples t-test. \(^\top\)Data in square brackets are ranges. SD=Standard deviation; BMI=Body mass index

Table 2: Contrast media volumes and injection rates

| Characteristic                  | Standard group | Individualized group | \( P \)   |
|--------------------------------|---------------|----------------------|---------|
| CM-volume (ml)*                | 55.0±0.0      | 54.2±4.8             | <0.05** |
| Injection rate (ml/s)*         | 3.5±0.0       | 4.1±0.3              | <0.05** |
| Number of patients             | 23            | 39                   |         |

*The data are presented as mean±SD. **P values calculated using nonparametric Mann-Whitney U-test. \( P \) values calculated using independentsamples t-test. PE=Pulmonary embolism; SD=Standard deviation; CM=Contrast media

Table 3: Attenuation values in main pulmonary trunk, right lower lobe and left lower lobe arteries, descending aorta, and superior vena cava

| Location              | Standard group\(^*\) | Individualized group\(^*\) | \( P^{**} \) |
|-----------------------|----------------------|-----------------------------|-------------|
| Main pul. trunk       | 422.1±147.4          | 442.9±147.7                 | 0.61        |
| RLL                   | 397.6±143.4          | 410.2±143.2                 | 0.26        |
| LLL                   | 404.1±142.2          | 419.6±137.5                 | 0.99        |
| Aorta                 | 275.5±119.7          | 261.6±98.7                  | 0.17        |
| SVC                   | 672.5±442.8          | 697.8±413.5                 | 0.79        |

*The data are presented as mean±SD. **P values calculated using independentsamples t-test. RLL=Right lower lobe; LLL=Left lower lobe; SVC=Superior vena cava; SD=Standard deviation
This method requires the optimal vascular enhancement. Many studies confirmed that a flow rate of 4 ml/s is sufficient for diagnostic CTPA. For vascular imaging, the increase of injection rate does affect peak enhancement and results in substantially higher intraluminal enhancement, therefore achieving optimal visualization of pulmonary vessels throughout the peripheral pulmonary branches.

Arterial enhancement depends on the iodine administration rate (or iodine flux), the amount of contrast media used as well on other patient-related aspects, for example, cardiac output and BMI. Iodine flux can be controlled by the injection flow rate (ml/s) and/or the iodine concentration of the contrast medium (mg iodine/ml). An increased delivery rate leads to greater arterial enhancement. Many studies confirmed that a flow rate of 4 ml/s is sufficient for diagnostic CTPA. For vascular imaging, the increase of injection rate does affect peak enhancement and results in substantially higher intraluminal enhancement, therefore achieving optimal visualization of pulmonary vessels throughout the peripheral pulmonary branches.

One of the most important patient-related factors affecting vascular enhancement is BMI. Numerous studies have examined the effect of BMI on vascular enhancement. The CM administered to a patient with higher BMI is more diluted than that administered to a patient with lower BMI due to the larger blood distribution volumes than in smaller patients. Thus, when an appropriate contrast enhancement is needed, theoretically, the amount of iodine should be adjusted for the body weight.

Our analysis showed that adjusting contrast media volume and flow rate to patient’s BMI allowed us to reduce the amount of contrast media for CTPA even in patients with high BMI. Even though we observed an increase of vascular attenuation by 4.8%, 7.4%, and 3.7% in the main pulmonary trunk, the right lobe artery, and left lower lobe artery, respectively, this difference was not significant. More obviously and in agreement with previously published data, the adjustment of flow rate (or iodine flux in other words) can help to increase vascular attenuation in the pulmonary territory. A qualitative analysis performed by two experienced readers yielded comparable results with regard to diagnostic reliability.

Some studies, such as Behrendt et al. reported, that the use of 300 mg I/ml CM results in better contrast enhancement than the use of 370 mg I/ml CM in CT of the chest. This, at the first sight, contradictory phenomenon is explained by higher viscosity with increasing iodine concentration. In our institution, a contrast agent with an iodine concentration of 400 mg I/ml is used for all contrast-enhanced CT protocols. The flow rates ranged from 3.3 ml/s to 5.5 ml/s and were at least in part substantially higher than recommended in the literature. Accordingly, the iodine flux (up to 2.2 g iodine/s) exceeded the current recommendation (<1.5 g iodine/s).

Contrast media volume and flow rate were automatically chosen by the power injector based on individual BMI. While the reasons for the automatic selection of high iodine delivery rates by the software remain unknown, we did not observe any significant disadvantages. The slightly higher contrast in the superior vena cava (SVC) did not impair the image quality substantially; however, the contrast agent remaining in the SVC did not contribute to the attenuation of the pulmonary arteries. Based on this observation, we hypothesize that the amount of contrast agent can be further reduced without impairing diagnostic reliability.

Isolated thromboembolism of the subsegmental pulmonary arteries occurs in 6%–30% of patients with PE. Since the diagnostic reliability of CTPA is mainly influenced by intravascular contrast enhancement, the use of individualized contrast administration protocols may...
improve visualization of small emboli, thereby improving
diagnostic accuracy, particularly in the evaluation of
peripheral pulmonary arteries. Our study showed a
significantly higher PE detection rate in the individualized
protocol’s group (P < 0.001). However, due to a lack of gold
standard, the interpretation of this observation is difficult. In
an attempt to minimize bias, we included all patients with
suspicion of pulmonary embolism in our study. However,
we cannot exclude a selection bias that may have resulted in
a higher detection rate of PE in Group 2. The software-based
technique used in our study is not widely available.
Moreover, the detailed underlying equations that are used
by the software have not been disclosed by the manufacturer.
Thus, our results cannot be translated easily to other
institutions or other, especially faster CT technology which
may potentially lead to a further reduction of contrast
volume further decreasing the risk of contrast related risks,
for example, renal failure. Tube voltage, another important
CT parameter, that substantially affects attenuation should
also be considered when individualizing injection protocols.
Thus, further prospective multicenter studies are necessary,
where patients are randomly assigned to either the standard
or individualized protocol to warrant the reproducibility
of our result in a larger cohort of patients of different age
and BMI and between different CT machines. Furthermore,
an individualization of contrast media application is
recommended not only in CTPA imaging but also in CT
angiographies of other vascular territories and should be
evaluated in additional studies.

CONCLUSION

An individualized CTPA protocol based on a patient’s BMI
reduced the contrast media volume and led to an increased
pulmonary artery enhancement improving image quality,
particularly in the evaluation of peripheral pulmonary
arteries. Thus, contrast media volumes in CTPA should be
adjusted for the patient’s BMI.

Acknowledgments

The authors of this study offer their most appreciations
toward Biometrics Department of Hannover Medical School
for help with the statistical data analysis.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

REFERENCES

1. Bělohlávek J, Dytrych V, Linhart A. Pulmonary embolism, part I:
Epidemiology, risk factors and risk stratification, pathophysiology,
clinical presentation, diagnosis and nonthrombotic pulmonary
embolism. Exp Clin Cardiol 2013;18:129-38.
2. Konstantinides S, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D,
Galié N, et al. 2014 ESC guidelines on the diagnosis and
management of acute pulmonary embolism. Eur Heart J
2014;35:3033-69.
3. Cohen AT, Agnelli G, Anderson FA, Arbelzu JL, Bergqvist D, Brecht JG,
et al. Venous thromboembolism (VTE) in Europe the number of
VTE events and associated morbidity and mortality. Thromb
Haemost 2007;98:756-64.
4. Torbicki A, Perrier A, Konstantinides S, Agnelli G, Galié N,
Pruszczczyk P, et al. 2008 Guidelines on the diagnosis and
management of acute pulmonary embolism. European Heart
Journal 2008;29:2276-315.
5. Pulivarthi S, Gurram MK. Effectiveness of d-dimer as a screening
test for venous thromboembolism: An update. N Am J Med Sci
2014;6:491-9.
6. Wilbur J, Shian B. Diagnosis of deep venous thrombosis and
pulmonary embolism. Am Fam Physician 2012;86:913-9.
7. Nance JW, Henzlter T, Meyer M, Apfaltrter P, Braunagel M, Krissak R,
et al. Optimization of contrast delivery for dual-energy computed
tomography angiography of the lungs in patients with suspected
pulmonary embolism. 10.1594/erc2011/C-0501.
8. Remy-Jardin M, Pistolesi M, Goodman LR, Gefter WB, Gottschalk A,
Mayo JR, et al. Management of suspected acute pulmonary
embolism in the era of CT angiography: A statement from the
fleischer society. RSNA 2007;245:315-29.
9. Ramadan SU, Kosar P, Sonmez I, Karahan S, Kosar U. Optimisation of
contrast medium volume and injection-related factors in CT
pulmonary angiography: 64-slice CT study, European Society of
Radiology Eur Radiol 2010;20:2100-07.
10. Raptopoulos V, Boiselle PM. Multi-detector row spiral CT
pulmonary angiography: Comparison with single-detector row
spiral CT. Radiology 2001;221:606-13.
11. Gattoni F, Tagliaferri B, Scali P, Brioschi S, Boioli F. Contrast
medium injection optimisation in spiral CT for the diagnosis of
pulmonary embolism, 2003;105(5-6):416-24.
12. Raskob GE, Silverstein R, Bratzler DW, Heit JA, White RH.
Surveillance for deep vein thrombosis and pulmonary embolism
recommendations from a national workshop. Am J Prev Med
2010;4 Suppl 38:S502-9.
13. Szucs-Farkas Z, Schaller C, Bensler S, Patak MA, Vock P,
Schindera ST. Detection of pulmonary emboli with CT angiography
at reduced radiation exposure and contrast material volume
comparison of 80 kVp and 120 kVp protocols in a matched cohort.
Investigative Radiol 2009;44:793-9.
14. Wittram C, Wollman AC, Shepard JA, Halpern E, Goodman LR.
Discordance between CT and angiography in the PIOPED II study.
Radiology 2007;244:883-9.
15. Kubo S, Tadamura E, Yamamuro M, Hosokawa R, Kimura T,
Kita T, et al. Thoracoabdominal-aortoiliac MDCT angiography
using reduced dose of contrast material. AJR Am J Roentgenol
2006;187:548-54.
16. Roggenland D, Peters SA, Lemburg SP, Holland-Letz T, Nicolas V,
Heyer CM. CT angiography in suspected pulmonary embolism:
Impact of patient characteristics and different venous lines
on vessel enhancement and image quality. Am J Roentgenol.
2008;190:W351-9.
17. Douma RA, Hofstee HM, Schaefer-Prokopc, van Waesberghe JHTM,
Lely RJ, Kamphuisen PW, et al. Comparison of 4- and 64-slice
CT scanning in the diagnosis of pulmonary embolism. Thromb
Haemost 2010;103:242-6.
18. Behrendt FF, Mahnken AH, Stanelz S, Seidensticker P, Jost E,
Günther RW, et al. Intraindividual comparison of contrast media
concentrations for combined abdominal and thoracic MDCT. AJR
20. Heiken JP, Brink JA, McClellan BL, Sagel SS, Crowe TM, Gaines MV. Dynamic incremental CT: Effect of volume and concentration of contrast material and patient weight on hepatic enhancement. Radiology 1995;195:353-7.

21. Awai K, Hori S. Effect of contrast injection protocol with dose tailored to patient weight and fixed injection duration on aortic and hepatic enhancement at multidetector row helical CT. Eur Radiol 2003;13:2155-60.

22. Schoellnast H, Deutschmann HA, Berhold A, Fritz GA, Schaffler GJ, Tillich M. MDCT angiography of the pulmonary arteries: Influence of body weight, body mass index, and scan length on arterial enhancement at different iodine flow rates. AJR 2006;187:1074-8.

23. Dean PB, Kivisaari L, Kormano M. Contrast enhancement pharmacokinetics of six ionic and nonionic contrast media. Invest Radiol 1983;18:368-74.

24. Yanaga Y, Awai K, Nakaura T, Utsunomiya D, Oda S, Hirai T, et al. Contrast material injection protocol with the dose adjusted to the body surface area for MDCT aortography. AJR Am J Roentgenol 2010;194:903-8.

25. Cademartiri F, de Monye C, Pugliese F, Mollet NR, Runza G, van der Lugt A, et al. High iodine concentration contrast material for noninvasive multislice computed tomography coronary angiography: Iopromide 370 versus iomeprol 400. Invest Radiol 2006;41:349-53.

26. Setty BN, Sahani DV, Ouellette-Piazzo K, Hahn PF, Shepard JO. Comparison of enhancement, image quality, cost, and adverse reactions using 2 different contrast medium concentrations for routine chest CT on 16-slice MDCT. J Comput Assist Tomogr 2006;30:818-22.

27. Nijkeuter M, Kwakkel-van ER, Kruip MJ. Incidence of diagnosis of subsegmental pulmonary emboli using multidetector row and single-detector row computed tomography, J Thromb Haemostasis 2008;6:384-6.